Erythroid-stimulating agents in cancer therapy: Potential dangers and biologic mechanisms

Journal of Clinical Oncology

Volumn 27, Issue 25, 2009, Pages 4217-4226

  Hadland, Brandon K ^a   Longmore, Gregory D ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ERYTHROPOIETIN RECEPTOR; FLUOROURACIL; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ANEMIA; ANGIOGENESIS; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLON CANCER; DRUG SAFETY; FIBROSARCOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; LEWIS CARCINOMA; NEUROFIBROSARCOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; VASCULAR DISEASE; ANIMAL; BLOOD; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG POTENTIATION; ERYTHROID CELL; METABOLISM; MORTALITY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REVIEW; RISK ASSESSMENT; THROMBOSIS; TREATMENT OUTCOME;

ANEMIA; ANIMALS; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; ERYTHROID CELLS; HEMATINICS; HEMOGLOBINS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ERYTHROPOIETIN; RISK ASSESSMENT; SIGNAL TRANSDUCTION; THROMBOSIS; TREATMENT OUTCOME;

EID: 70249134095     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.6945     Document Type: Article

References (86)

1. Caro JJ, Salas M, Ward A, et al: Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 91:2214-2221, 2001
2. Spano JP, Khayat D: Treatment options for anemia, taking risks into consideration: Erythropoiesis-stimulating agents versus transfusions. Oncologist 13: 27-32, 2008 (suppl 3)
3. Thews O, Koenig R, Kelleher DK, et al: Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 78:752-756, 1998
4. Silver DF, Piver MS: Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect. Gynecol Oncol 73: 280-284, 1999
5. Bohlius J, Wilson J, Seidenfeld J, et al: Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708-714, 2006
6. Henke M, Laszig R, Rube C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260, 2003
7. Henke M, Mattern D, Pepe M, et al: Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24:4708-4713, 2006
8. Elliott S, Busse L, Bass MB, et al: Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107:1892-1895, 2006
9. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 23:5960-5972, 2005
10. Wright JR, Ung YC, Julian JA, et al: Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027-1032, 2007
11. Smith RE Jr, Aapro MS, Ludwig H, et al: Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26: 1040-1050, 2008
12. Aapro M, Leonard RC, Barnadas A, et al: Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: Results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 26: 592-598, 2008
13. Bennett CL, Silver SM, Djulbegovic B, et al: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914-924, 2008
14. Littlewood TJ, Bajetta E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001
15. Grote T, Yeilding AL, Castillo R, et al: Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 23:9377-9386, 2005
16. Vansteenkiste J, Pirker R, Massuti B, et al: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211-1220, 2002
17. Witzig TE, Silberstein PT, Loprinzi CL, et al: Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606-2617, 2005
18. Chang J, Couture F, Young S, et al: Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23: 2597-2605, 2005
19. Savonije JH, van Groeningen CJ, van Bochove A, et al: Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial. Eur J Cancer 41:1560-1569, 2005
20. US Food and Drug Administration. Aranesp (darbepoetin alfa) January 2007. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm150816.htm
21. Sakanaka M, Wen TC, Matsuda S, et al: In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 95:4635-4640, 1998
22. Brines M, Grasso G, Fiordaliso F, et al: Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 101:14907-14912, 2004
23. Brines M, Patel NS, Villa P, et al: Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 105:10925-10930, 2008
24. Hilton DJ, Watowich SS, Murray PJ, et al: Increased cell surface expression and enhanced folding in the endoplasmic reticulum of a mutant erythropoietin receptor. Proc Natl Acad Sci U S A 92:190-194, 1995
25. Masuda S, Nagao M, Takahata K, et al: Functional erythropoietin receptor of the cells with neural characteristics: Comparison with receptor properties of erythroid cells. J Biol Chem 268:11208-11216, 1993
26. Um M, Gross AW, Lodish HF: A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 19:634-645, 2007
27. Sinclair AM, Rogers N, Busse L, et al: Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 98:1059-1067, 2008
28. Zon LI, Youssoufian H, Mather C, et al: Activation of the erythropoietin receptor promoter by transcription factor GATA-1. Proc Natl Acad Sci U S A 88:10638-10641, 1991
29. Jelkmann W, Bohlius J, Hallek M, et al: The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 67:39-61, 2008
30. Rogers HM, Yu X, Wen J, et al: Hypoxia alters progression of the erythroid program. Exp Hematol 36:17-27, 2008
31. Maxwell PH: Hypoxia-inducible factor as a physiological regulator. Exp Physiol 90:791-797, 2005
32. Hardee ME, Arcasoy MO, Blackwell KL, et al: Erythropoietin biology in cancer. Clin Cancer Res 12:332-339, 2006
33. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
34. Coleman TR, Westenfelder C, Togel FE, et al: Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci U S A 103:5965-5970, 2006
35. Fuste B, Serradell M, Escolar G, et al: Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 88:678-685, 2002
36. Stohlawetz PJ, Dzirlo L, Hergovich N, et al: Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 95:2983-2989, 2000
37. Lindenblatt N, Menger MD, Klar E, et al: Darbepoetin-alpha does not promote microvascular thrombus formation in mice: Role of eNOS-dependent protection through platelet and endothelial cell deactivation. Arterioscler Thromb Vasc Biol 27:1191-1198, 2007
38. Farrell F, Lee A: The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9:18-30, 2004 (suppl 5)
39. Arcasoy MO: The non-haematopoietic biological effects of erythropoietin. Br J Haematol 141:14-31, 2008
40. Westenfelder C, Baranowski RL: Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58:647-657, 2000
41. Acs G, Acs P, Beckwith SM, et al: Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61:3561-3565, 2001
42. Yasuda Y, Fujita Y, Musha T, et al: Expression of erythropoietin in human female reproductive organs. Ital J Anat Embryol 106:215-222, 2001
43. Arcasoy MO, Amin K, Karayal AF, et al: Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82:911-918, 2002
44. Westphal G, Niederberger E, Blum C, et al: Erythropoietin and G-CSF receptors in human tumor cells: Expression and aspects regarding functionality. Tumori 88:150-159, 2002
45. Acs G, Zhang PJ, McGrath CM, et al: Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162:1789-1806, 2003
46. Batra S, Perelman N, Luck LR, et al: Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83:1477-1487, 2003
47. Yasuda Y, Fujita Y, Matsuo T, et al: Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24:1021-1029, 2003
48. Feldman L, Wang Y, Rhim JS, et al: Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 66:135-145, 2006
49. Sinclair AM, Todd MD, Forsythe K, et al: Expression and function of erythropoietin receptors in tumors: Implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 110: 477-488, 2007
50. Acs G, Chen M, Xu X, et al: Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett 214:243-251, 2004
51. Belenkov AI, Shenouda G, Rizhevskaya E, et al: Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 3:1525-1532, 2004
52. Liu WM, Powles T, Shamash J, et al: Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 23: 981-990, 2004
53. Pajonk F, Weil A, Sommer A, et al: The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene 23:8987-8991, 2004
54. Lai SY, Childs EE, Xi S, et al: Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 24:4442-4449, 2005
55. Lester RD, Jo M, Campana WM, et al: Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem 280: 39273-39277, 2005
56. Mohyeldin A, Lu H, Dalgard C, et al: Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 7:537-543, 2005
57. Phillips TM, Kim K, Vlashi E, et al: Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia 9:1122-1129, 2007
58. Berdel WE, Oberberg D, Reufi B, et al: Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol 63:5-8, 1991
59. Rosti V, Pedrazzoli P, Ponchio L, et al: Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 78:208-212, 1993
60. Laugsch M, Metzen E, Svensson T, et al: Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 122:1005-1011, 2008
61. Tóvári J, Gilly R, Raso E, et al: Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models. Cancer Res 65:7186-7193, 2005
62. LaMontagne KR, Butler J, Marshall DJ, et al: Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 5:347-355, 2006
63. Hardee ME, Rabbani ZN, Arcasoy MO, et al: Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther 5:356-361, 2006
64. Stüben G, Pottgen C, Knuhmann K, et al: Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 55:1358-1362, 2003
65. Stüben G, Thews O, Pottgen C, et al: Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 127:346-350, 2001
66. Shannon AM, Bouchier-Hayes DJ, Condron CM, et al: Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma. Br J Cancer 93:224-232, 2005
67. Kelleher DK, Mattheinsen U, Thews O, et al: Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 56:4728-4734, 1996
68. Ning S, Hartley C, Molineux G, et al: Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia. Cancer Res 65:284-290, 2005
69. Sigounas G, Sallah S, Sigounas VY: Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model. Cancer Lett 214:171-179, 2004
70. Kjellén E, Sasaki Y, Kjellstrom J, et al: Recombinant erythropoietin beta enhances growth of xenografted human squamous cell carcinoma of the head and neck after surgical trauma. Acta Otolaryngol 126:545-547, 2006
71. Yasuda Y, Musha T, Tanaka H, et al: Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 84:836-843, 2001
72. Hardee ME, Kirkpatrick JP, Shan S, et al: Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer 93:1350-1355, 2005
73. Hardee ME, Cao Y, Fu P, et al: Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One 2:e549, 2007
74. Okazaki T, Ebihara S, Asada M, et al: Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 10:932-939, 2008
75. Parsa CJ, Matsumoto A, Kim J, et al: A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112:999-1007, 2003
76. Heeschen C, Aicher A, Lehmann R, et al: Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102: 1340-1346, 2003
77. Carlini RG, Reyes AA, Rothstein M: Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 47:740-745, 1995
78. Ribatti D, Presta M, Vacca A, et al: Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627-2636, 1999
79. Carlini RG, Alonzo EJ, Dominguez J, et al: Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 55:546-553, 1999
80. Kirkeby A, Torup L, Bochsen L, et al: High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO). Thromb Haemost 99:720-728, 2008
81. Borsig L: The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther 8:1247-1255, 2008
82. Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107, 2002
83. Gascon P: Safety update on erythropoiesis-stimulating agents: Trials within and outside the accepted indications. Oncologist 13:4-10, 2008 (suppl 3)
84. US Food and Drug Administration: Epogen. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2008/103234s5195sPI.pdf
85. US Food and Drug Administration: Procrit. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2008/103234s5196PI.pdf
86. US Food and Drug Administration: Aranesp. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2007/103951s5164lbl.pdf